This preliminary illustration of the synergistic mechanism of the MEK inhibitor trametinib combined with the RTK inhibitor anlotinib provides a theoretical basis for the clinical translation of this novel combined strategy for KRAS-mutant NSCLC. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.